Curevac N.V. (CVAC)

Trade CVAC now with
5/25/2022 7:52:58 AM CureVac Partners With MyNEO To Identify Novel Antigen Targets
5/25/2022 7:41:11 AM CureVac Q1 Pre-tax Loss EUR 15.2 Mln Vs Loss EUR 112.2 Mln Last Year
4/28/2022 9:45:48 AM CureVac Q4 Revenues EUR 41.2 Mln Increase From EUR 6.0 Mln Last Year
4/21/2022 7:59:15 AM CureVac, GSK's Bivalent MRNA Vaccine Shown To Be Highly Effective Against SARS-CoV-2 Variants
4/11/2022 8:52:40 AM CureVac, GSK Reach Pandemic Preparedness Contract With German Government
3/30/2022 8:54:50 AM CureVac, GSK Start Clinical Development Of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
3/1/2022 9:10:08 AM CureVac Forms Fully-Owned Company Dedicated To Advancing The RNA Printer
2/10/2022 10:06:01 AM CureVac Doses First Participant In Phase 1 Study With Multivalent Influenza Vaccine Candidate
1/17/2022 7:06:38 AM CureVac Chief Technology Officer Mariola Fotin-Mleczek To Resign, Effective January 31, 2022
11/18/2021 6:27:47 AM CureVac Publishes In Nature Preclinical Data Of Second-Generation COVID-19 Candidate, CV2CoV
10/12/2021 7:18:27 AM CureVac To Withdraw 1st-generation COVID-19 Vaccine Candidate, CVnCoV From Approval Process With EMA
9/14/2021 7:30:10 AM CureVac Announces Decision To Adjust Long-term Footprint Of External European Network For MRNA Product Pipeline